Business
Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders
NEW YORK, March 23, 2026--Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its executive leadership team and the in-licensing of worldwide rights from AstraZeneca to a Phase 3–ready novel chemical entity (NCE), which is a component of Amani’s lead program, AM-01.
About this update from Astrazeneca Plc
[{"type":"text","content":"NEW YORK, March 23, 2026--(BUSINESS WIRE)--Amani Therapeutics, a newly formed biotechnology company backed by RTW Investments, today announced the closing of a $25 million Series A financing. The company also announced the appointment of its executive leadership team and the in-licensing of worldwide rights from AstraZeneca to a Phase 3–ready novel chemical entity (NCE), which is a component of Amani’s lead program, AM-01.","length":426,"tagName":"p"},{"type":"text","content":"Amani’s mission is to develop highly efficacious, safer medicines for people living with serious neuropsychiatric disorders.","length":124,"tagName":"p"},{"type":"text","content":"About AM-01","length":11,"tagName":"p"},{"type":"text","content":"AM-01 is a fixed-dose combination product that includes clozapine and a Phase 3–ready NCE with worldwide rights in-licensed from AstraZeneca. Amani believes AM-01 has the potential to deliver clozapine’s unmatched efficacy for patients with schizophrenia while addressing clozapine’s most significant safety liability—severe neutropenia—and the burdensome blood-monitoring that limit its use.","length":392,"tagName":"p"},{"type":"text","content":"Clozapine remains the only medication proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. Despite its clinical benefits, it is profoundly underutilized due to safety concerns and monitoring requirements.","length":316,"tagName":"p"},{"type":"text","content":""Our understanding of the mechanism of clozapine-induced neutropenia, supported by results from our preclinical models, leads us to believe we have identified a solution to the decades-long challenge of developing a safer clozapine," said Carla Canuso, MD, Chief Medical Officer of Amani Therapeutics. "By combining clozapine with the NCE licensed from AstraZeneca, we aim to mitigate the risk of neutropenia and the associated blood-monitoring requirements, while preserving clozapine’s efficacy."","length":518,"tagName":"p"},{"type":"text","content":"Executive Appointments","length":22,"tagName":"p"},{"type":"text","content":"Rob Swoboda joins Amani as Chief Operating Officer, bringing deep operational, development, and commercialization experience from leadership roles at Karuna Therapeutics, ...